Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), focusing on its impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.